/* */ PELVIPHARM - SPECIALIZED PRECLINICAL EXPERTISE in male and female sexual functions and diseases of the lower urinary tract
Receive our news


May 24th - 2011

Take Home Message on “Sexual function and dysfunction” session - AUA 2011

Pelvipharm is quoted in the “Take Home Messages” on “Sexual function and dysfunction” presented by Gerald Brock at the AUA (American Urological Association) in Washington, DC the may 17th, 2011.

Pelvipharm’s study “Experimental evidence that a combination of sGC stimulator BAY 60-4552 and PDE5 inhibitor vardenafil might salvage patients with insufficient response to PDE5 inhibitors after cavernous nerve injury” was highlighted as the most innovative research in the “Sexual function and dysfunction”session.

January 11th - 2011

Future presentation at the EAU 2011

Pelvipharm at the EAU (European Association of Urology) in Vienna, Austria, 18 - 22 March 2011.

Pelvipharm will present 1 Poster:

Please come and see us, we will be happy to discuss our results with you and potential applications for you.


February 7th - 2011

Bio-Europe Spring in Milan, March 2011

Pelvipharm will be represented by Delphine Behr-Roussel at the next BIO-Europe Spring meeting in Milan, March 14-16 2011. We warmly invite you to take this opportunity to learn more about our services.

If you’d like to set up a specific meeting at any time throughout the conference, please email staffpelvipharm@pelvipharm.com and we will be happy to assist you.


November 26th - 2010

Recently accepted paper in Eur Urol

Vardenafil decreases bladder afferent nerve activity in unanesthetized, decerebrate, spinal cord-injured rats.
Behr-Roussel D, Oger S, Caisey S, Sandner P, Bernabé J, Alexandre L, Giuliano F.
European Urology, 59(2):272-9

October 4th - 2010

Recently accepted review in J Sex Med

Experimental Models for the Study of Female and Male Sexual Function.
Giuliano F, Pfaus J, Balasubramanian S, Hedlund P, Hisasue S, Marson L, Wallen K.
J Sex Med, 2010 sep, Vol 7, Issue 9, pages 2970-2995.

Page 12 / 20     Previous      1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  Next 
TEL +331 704 293 39
FAX + 331 704 295 10